IL4 and neoplasm: This conclusion is based on a spatial functional genomics screen (Perturb‐map) performed in preclinical ovarian cancer models, which recapitulated tumor heterogeneity and revealed that IL‐4 directs localized TME composition, driving clonal selection and immunotherapy resistance.